Patents Assigned to Oncotyrol-Center for Personalized Cancer Medicine GmbH (Ltd.)
  • Medical intervention in haematological cancers
    Patent number: 8501734
    Abstract: The present invention relates to the medical and pharmaceutical use of substituted 1H-imidazo[4,5-c]quinolin-4-amines, in particular Imiquimod® and Gardiquimod®, alone or preferably in combination with Akt inhibitors, in particular with Akti1/2 and AktX, and most preferably with Akti1/2, in the treatment, prevention and/or amelioration of haematological cancers, in particular multiple myeloma disorders or B-cell disorders, and most particular in the therapy of multiple myeloma.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: August 6, 2013
    Assignee: Oncotyrol-Center for Personalized Cancer Medicine GmbH (Ltd.)
    Inventors: Lukas Huber, Simon Schnaiter, Inge Tinhofer, Karin Jöhrer, Richard Greil